Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Associations Between Inflammatory and Catecholamine Markers and Clinical Outcomes in People with Post-Acute SARS-CoV-2 Infection.

International journal of general medicine·2025

Same author

A pilot investigation of the impact of acute mental and physical fatigue exposure on inflammatory cytokines and state fatigue level in breast cancer survivors.

BMC women's health·2025

Same author

The impact of hepatitis B and C positive serologies on the outcomes of non-hepatic solid organ transplantation in the United States.

Journal of viral hepatitis·2023

Same author

The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease.

Hepatology communications·2023

Same author

Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study.

Hepatology communications·2023

Same author

Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.

Journal of hepatology·2023

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Emerging therapies for hepatitis C virus.

Aybike Birerdinc¹, Zobair M Younossi

¹Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.

Expert Opinion on Emerging Drugs

|July 16, 2010

Summary

New Hepatitis C Virus (HCV) therapies show promise in improving sustained virological response (SVR) rates. Combination treatments may shorten duration and increase viral clearance for HCV patients.

Area of Science:

Hepatitis C Virus (HCV) therapeutics development.
Antiviral drug discovery and clinical trials.

Background:

Hepatitis C Virus (HCV) affects 170 million globally, causing chronic liver disease, cirrhosis, and hepatocellular carcinoma.
Current standard treatment (pegylated IFN-α + ribavirin) yields limited sustained virological response (SVR) rates, especially for HCV genotype 1 and certain populations.
The high prevalence and low cure rates of existing therapies result in a significant global health burden.

Purpose of the Study:

To review novel therapeutic compounds for Hepatitis C Virus (HCV) treatment.
To highlight advancements in HCV drug development and their potential to address current treatment limitations.

Main Methods:

Review of compounds in advanced clinical development for HCV.
Focus on novel agents including HCV protease inhibitors, HCV polymerase inhibitors (nucleoside and non-nucleoside analogs), and cyclophilin inhibitors.

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Experiment Videos

Last Updated: Jun 11, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Main Results:

Novel HCV therapeutics in late-stage development show promise in overcoming challenges faced by earlier treatments.
These new agents offer potential improvements over the current standard of care for Hepatitis C Virus.

Conclusions:

Clinical trial data for novel HCV agents are encouraging.
Combination therapies involving these new agents may shorten treatment duration and enhance viral clearance when used with existing treatments.